Advertisement

International Journal of Clinical Pharmacy

, Volume 33, Issue 6, pp 925–928 | Cite as

Good practice in antibiotic use: what about linezolid in a French university hospital?

  • Guillaume Aubin
  • Christine Lebland
  • Stéphane Corvec
  • Patrick Thomaré
  • Gilles Potel
  • Jocelyne Caillon
  • Dominique NavasEmail author
Short Research Report

Abstract

Objective Linezolid represents an important advance in the treatment of methicillinresistant staphylococci. Its effectiveness should be preserved by appropriate uses. The aims of this survey were to describe the use of linezolid in clinical practice and to assess its overall safety. Methods This retrospective observational study included patients treated with linezolid in 2008 in all departments at the CHU Nantes. A data-collection card was completed using the patients’ medical files. Results A total of 179 patients from 23 different departments were included. Fifty-four per cent of indications were outside the Marketing Authorization criteria, and were mainly osteoarticular infections and septicaemia (22% and 8% of total prescriptions, respectively). Inefficacy of first-line antibiotic treatment (23%) and alterations in renal function (23%) were the main reasons for using linezolid, which was prescribed as a first-line therapy in 28% of patients. Fifty-three per cent of infections were documented microbiologically, of which 58% were due to a methicillin-resistant Staphylococcus. Conclusions Linezolid seems to be a possible therapeutic strategy in case of multiresistant bacteria and/or complex clinical situations. Because many prescriptions fall outside the Marketing Authorization criteria, this study highlights the need to have clinical data available for such situations.

Keywords

Antibiotic use evaluation France Good practice Hospital Linezolid Methicillin-resistant staphylococcus 

Notes

Funding

None.

Conflicts of interest

None to declare.

References

  1. 1.
    Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in paediatric patients: an overview. Pediatr Infect Dis J. 2003;22(9 Suppl):S153–7.PubMedGoogle Scholar
  2. 2.
    Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;35(1):3–12.Google Scholar
  3. 3.
    Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002;46(5):1475–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Walkey AJ, O’Donnell MR, Wiener RS. Linezolid versus glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest. 2011;139(5):1148–55.Google Scholar
  5. 5.
    Tedla FM, Salifu M, Friedman EA. Successful treatment of vancomycin-resistant enterococcal peritonitis with linezolid in a kidney transplant patient: a case report and review of the literature. Perit Dial Int. 2004;24(1):70–2.PubMedGoogle Scholar
  6. 6.
    Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopaedic infections: a prospective case series. Diagn Microbiol Infect Dis. 2007;59(2):173–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: non inferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48(2):203–12.PubMedCrossRefGoogle Scholar
  8. 8.
    Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42(5):597–607.PubMedCrossRefGoogle Scholar
  9. 9.
    Wagenlehner FM, Naber KG. New drugs for Gram-positive uropathogens. Int J Antimicrob Agents. 2004;24(Suppl 1):S39–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis. 2001;33(4):477–82.PubMedCrossRefGoogle Scholar
  11. 11.
    Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58(2):273–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Ziglam HM, Elliott I, Wilson V, Hill K, Nathwani D. Clinical audit of linezolid use in a large teaching hospital. J Antimicrob Chemother. 2005;56(2):423–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Ross JE, Farrell DJ, Mendes RE, Sader HS, Jones RN. Eight-year (2002–2009) summary of the linezolid (Zyvox(R) annual appraisal of potency and spectrum; ZAAPS) program in European countries. J Chemother. 2011;23(2):71–6.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Guillaume Aubin
    • 1
    • 2
  • Christine Lebland
    • 3
  • Stéphane Corvec
    • 1
    • 2
  • Patrick Thomaré
    • 3
  • Gilles Potel
    • 2
  • Jocelyne Caillon
    • 1
    • 2
  • Dominique Navas
    • 2
    • 3
    Email author
  1. 1.Service de Bactériologie-HygièneCHU de NANTESNantes Cedex 1France
  2. 2.EA 3826 ‘Thérapeutiques Cliniques et Expérimentales des Infections’Faculté de MédecineNantesFrance
  3. 3.Pharmacie à Usage IntérieurCHU Hôtel-DieuNantes Cedex 1France

Personalised recommendations